Mandate

Vinge has advised the lead investor ARCH Venture Partners in Moleculent’s $26 million Series A financing

June 19, 2024

Moleculent AB, a company pioneering technology to study the communication between cells in human tissue, has closed its oversubscribed $26 million Series A financing. The round was led by ARCH Venture Partners and co-led by Eir Ventures with participation from the company’s existing investors.

ARCH Venture Partners creates and invests in groundbreaking life science and technology companies. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories.

The Vinge team primarily consisted of Johan Larsson, Maria Dahlin Kolvik, Stojan Arnerstål, David Olander, Johan Gavelin, Olof Löfvenberg and Alice Göransson.

Related

Vinge advises Stendörren in connection with issuance of green capital securities

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of green capital securities in an amount of SEK 400 million (within a framework of SEK 800 million).
May 07, 2026

Vinge represents Cinven in connection with the acquisition of Ongoing Warehouse

Vinge has represented the international private equity firm Cinven in connection with its acquisition of Ongoing Warehouse.
May 06, 2026

Vinge advises Fazer in connection with its acquisition of Aroma

Fazer has entered into an agreement to acquire Konfektyrfabriken Aroma AB, a Swedish confectionery manufacturer known for its classic candy products such as Geléhallon, Hallonbåtar, Röda Hjärtan and Gräddkola. The acquisition strengthens Fazer's position in the Swedish confectionery market, particularly within pick & mix, packed candy, and seasonal products. The acquisition is subject to customary regulatory approvals.
May 06, 2026